CASE STUDY
Monday, October 07
06:00 PM - 06:30 PM
Live in Berlin
Less Details
The industry is experimenting with AI. There are first use cases and the first pilots in RWE, HEOR and other fields. But what about Market Access? Are we as the function at the point where we can start implementing AI? In this presentation, Marco Rauland will take the audience onto the journey into the future and see what AI in Market Access could (or couldn’t) look like and see how we can get there.
In this presentation you will learn:
Marco Rauland has more than 25 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck Marco was Vice President Europe of GfK's Market Access practice. Before that Marco was the Global Head of the Pricing, Access and Reimbursement practice of Genactis and Senior Director of the Pricing and Reimbursement Business Unit at TNS Healthcare (now Kantar Group).
Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.